Rothbarth, Ph.H.

hbsag clinic anti-hbc hepatitis study 1-0 infection number women risk factors std clinic half year partner prevalence vaccination vaccine contact netherland drug use group influenza university hospital rotterdam subject 50 mg gmdp factor disease virus population table month hbv markers hepatitis b side-effects risk groups influenza vaccine rotterdam model country visitor hbsag positivity history individual nursing home residents hbv infection intervention marker health 3 months hospital hbv infections university association variable hepatitis b vaccination std clinic attendants symptom std clinic population result std clinics effect titre post-vaccination orogenital contact screening patient hbv prevalence 4 weeks positivity drug users resident nursing lifetime analyses antigen 3 days blood cell counts information group.bmj.com department duynhoven